Canada markets close in 3 hours 1 minute

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1709+0.1009 (+9.26%)
As of 12:58PM EDT. Market open.

Biofrontera Inc.

120 Presidential Way
Suite 330
Woburn, MA 01801
United States
781-245-1325
https://www.biofrontera-us.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Dr. Hermann Luebbert Ph.D.CEO, President & Executive Chairman733.23kN/A1956
Mr. Eugene Frederick Leffler IIIChief Financial Officer378.58kN/A1985
Ms. Erica F. Gates CPA, M.B.A.Senior Director of Finance & Principal Accounting OfficerN/AN/AN/A
Mr. Jon Lyons M.B.A., Ph.D.Vice President of Scientific & Medical AffairsN/AN/AN/A
Ms. Alycia TorresVice President of AdministrationN/AN/AN/A
Mr. Daniel Hakansson J.D.General Counsel & Head of ComplianceN/AN/AN/A
Ms. Samantha WiddicombeSenior Director of Strategic Accounts & CommunicationsN/AN/AN/A
Mr. Mark BaldygaVice President of Sales & MarketingN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.